Video: Latest Treatment for Hep C.

Vasodilan

Generic Name: isoxsuprine hydrochloride
Dosage Form: Tablets, USP

Vasodilan®
(isoxsuprine HCl tablets, USP)

INDICATIONS

Based on a review of this drug by the National Academy of Sciences-National Research and/or other information, the FDA has classified the indications as follows:

Slideshow: Worried About Ebola? You’re More Likely to Get These 10 Serious Infections

Possibly Effective:

  1. For the relief of symptoms associated with cerebrovascular insufficiency.
  2. In peripheral vascular disease of arteriosclerosis obliterans, thromboangitis obliterans (Buerger's disease) and Raynaud's disease.

Final classification of the less-than-effective indications requires further investigation.

COMPOSITION

Vasodilan (isoxsuprine HCl tablets, USP) 10 mg and 20 mg. These tablets contain the following inactive ingredients: acacia, dibasic calcium phosphate, lactose, magnesium stearate, starch (corn), and talc.

Vasodilan Dosage and Administration

Oral: 10 to 20 mg, three or four times daily.

CONTRAINDICATIONS AND CAUTIONS

Oral

There are no known contraindications to oral use when administered in recommended doses. Vasodilan should not be given immediately postpartum or in the presence of arterial bleeding.

Adverse Reactions

On rare occasion oral administration of the drug has been associated in time with the occurrence of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash. If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with isoxsuprine, a causal relationship can be neither confirmed nor refuted.

β-Adrenergic receptor stimulants such as isoxsuprine hydrochloride have been used to inhibit pre-term labor. Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received isoxsuprine. Pulmonary edema has been reported in mothers treated with β-stimulants. Vasodilan (isoxsuprine HCl tablets, USP) is neither approved nor recommended for use in the treatment of premature labor.

SUPPLIED

Vasodilan® (isoxsuprine HCl tablets, USP)

10 mg

Bottles of 100         NDC 0087-0543-01

Bottles of 1000       NDC 0087-0543-02

Unit Dose               NDC 0087-0543-05

Vasodilan® (isoxsuprine HCl tablets, USP)

20 mg

Bottles of 100         NDC 0087-0544-01

Bottles of 1000       NDC 0087-0544-06

MeadJohnson Pharmaceuticals

A Bristol-Myers Squibb Company, Princeton, New Jersey 08543 U.S.A.

Vasodilan 
isoxsuprine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) 0087-0543
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
isoxsuprine hydrochloride (isoxsuprine) isoxsuprine 10 mg
Inactive Ingredients
Ingredient Name Strength
acacia  
dibasic calcium phosphate  
lactose  
magnesium stearate  
starch (corn)  
talc  
Product Characteristics
Color WHITE (WHITE) Score no score
Shape ROUND (ROUND) Size 9MM
Flavor Imprint Code MJ;543;10
Contains         
Coating false Symbol false
Packaging
# Item Code Package Description
1 NDC:0087-0543-01 100 TABLET (100 TABLET) in 1 BOTTLE
2 NDC:0087-0543-02 1000 TABLET (1000 TABLET) in 1 BOTTLE
3 NDC:0087-0543-05 100 TABLET (100 TABLET) in 1 BLISTER PACK
Vasodilan 
isoxsuprine hydrochloride tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) 0087-0544
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
isoxsuprine hydrochloride (isoxsuprine) isoxsuprine 20 mg
Inactive Ingredients
Ingredient Name Strength
acacia  
dibasic calcium phosphate  
lactose  
magnesium stearate  
starch (corn)  
talc  
Product Characteristics
Color WHITE (WHITE) Score no score
Shape ROUND (ROUND) Size 10MM
Flavor Imprint Code MJ;544;20
Contains         
Coating false Symbol false
Packaging
# Item Code Package Description
1 NDC:0087-0544-01 100 TABLET (100 TABLET) in 1 BOTTLE
2 NDC:0087-0544-06 1000 TABLET (1000 TABLET) in 1 BOTTLE
Labeler - Bristol-Myers Squibb Company
Revised: 09/2006
 
Bristol-Myers Squibb Company
Hide
(web1)